allopurinol / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 0 Diseases   61 Trials   61 Trials   3860 News 


«12345678910111213...5758»
  • ||||||||||  ampicillin / Generic mfg., allopurinol / Generic mfg., amoxicillin / Generic mfg.
    Journal:  Chronic and Acute Drug-Induced Hypersensitivity Syndrome in a Rural Patient With Cytomegalovirus Infection: A Case Report. (Pubmed Central) -  Jul 1, 2024   
    Upon admission, amoxicillin was discontinued, and prednisolone and antiviral treatment were initiated...A drug-induced lymphocyte stimulation test confirmed hypersensitivity to both ampicillin and allopurinol...Viral infections like cytomegalovirus can complicate DIHS diagnosis and treatment, necessitating a comprehensive approach. This case highlights the importance of considering DIHS in differential diagnoses and the complexities of managing it alongside co-infections in rural healthcare settings.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Journal:  Gout, beyond the joint: How should we treat it? (Pubmed Central) -  Jun 30, 2024   
    This requires the sustained achievement of uricemia levels below 6mg/dl. We will also review preventive and flares treatment, as well as the role of patient education in terms of both lifestyle and dietary habits and adherence to pharmacological treatment.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  A Genome-Wide Association Study of Oxypurinol Concentrations in Patients Treated with Allopurinol. (Pubmed Central) -  Jun 27, 2024   
    Our results are consistent with prior findings regarding the difficulty in identifying genetic determinants of drug concentrations or pharmacokinetics of allopurinol and its metabolites, as well as allopurinol daily dosing. Given the size of this genome-wide study, collaborative investigations involving larger and diverse cohorts may be required to further identify pharmacogenomic determinants of allopurinol and measure their clinical relevance to personalize allopurinol therapy.
  • ||||||||||  allopurinol / Generic mfg.
    Beyond urate lowering: neuroprotective potential of Allopurinol (Exhibit (Pennsylvania Convention Center); In-Person) -  Jun 19, 2024 - Abstract #AAIC2024AAIC_4987;    
    Evidence - based studies reveal allopurinol, a xanthine oxidase inhibitor, to have a neuroprotective potential against Alzheimer's disease. Based on the current perspective, further research needs to be conducted in a clinical setting.
  • ||||||||||  allopurinol / Generic mfg.
    Exploring potential of Allopurinol in Dementia of Alzheimer's type (Exhibit (Pennsylvania Convention Center); In-Person) -  Jun 19, 2024 - Abstract #AAIC2024AAIC_3131;    
    Based on the current perspective, further research needs to be conducted in a clinical setting. The results suggest that the neuroprotective effects of allopurinol in STZ-induced Alzheimer's-type dementia might be attributed to anticholinesterase, antioxidative, and anti-inflammatory effects.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Glucoconjugated monoterpene indole alkaloids with xanthine oxidase inhibitory activity from Ophiorrhiza japonica. (Pubmed Central) -  Jun 13, 2024   
    The alkaloids 2 and 3, both of which have a pentacyclic zwitterionic system, were more active than the reference inhibitor, allopurinol (IC50 = 11.1 ?M) with IC50 values of 1.0 ?M, and 2.5 ?M, respectively. Structure-activity relationships analyses confirmed that the carbonyl group at C-14 was a key functional group responsible for the inhibitory effects of these alkaloids.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Preclinical, Journal:  Exploring Asphodelus microcarpus as a Source of Xanthine Oxidase Inhibitors: Insights from In Silico and In Vitro Studies. (Pubmed Central) -  Jun 13, 2024   
    These findings underscore the potential therapeutic significance of A. microcarpus in managing conditions related to XO activity. The research contributes valuable insights into the health-promoting properties of A. microcarpus and its potential application in natural medicine, presenting a promising avenue for further exploration in disease management.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Tophaceous gout. (Pubmed Central) -  Jun 13, 2024   
    Hyperuricemic patients (?7.8?mg/dL) can develop polyarticular tophaceous gout from intermittent arthritis if untreated. Acute flares and tophi development can be avoided by lowering blood urate levels with xanthine oxidase inhibitors.
  • ||||||||||  Zurampic (lesinurad) / AstraZeneca, Uriadec (topiroxostat) / Fuji Yakuhin, Suzuken
    Preclinical, Journal:  Evaluation of the inhibitory effects of antigout drugs on human carboxylesterases in vitro. (Pubmed Central) -  Jun 4, 2024   
    In silico docking showed that hydrogen bonds and hydrophobic interactions contributed to the intermolecular interactions of antigout drugs on CESs. Therefore, vigilant monitoring of potential drug-drug interactions (DDIs) is imperative when co-administering antigout drugs in clinical practice.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  The Tophus Impact Questionnaire (TIQ-20): responsiveness to change during urate-lowering therapy. (Pubmed Central) -  Jun 3, 2024   
    For people with tophaceous gout treated with allopurinol using a treat-to-target serum urate approach, improvements in TIQ-20 occurred, as did improvements in physical and imaging tophus measures. These findings demonstrate that the TIQ-20 is a responsive patient-reported instrument of tophus impact.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  What is allopurinol "failure" and what should we do about it? (Pubmed Central) -  Jun 2, 2024   
    In this review, we provide a framework for assessing allopurinol "failure", which includes failure of allopurinol to control serum urate concentrations, failure of allopurinol to control clinical symptoms, and failure of allopurinol due to an adverse drug reaction. Understanding the causes of allopurinol "failure" underpins the approach required to turn "failure" into "success" in gout management.
  • ||||||||||  prednisone / Generic mfg., colchicine / Generic mfg., allopurinol / Generic mfg.
    IS GOUT ASSOCIATED WITH AN EXCESS FRACTURE RISK? () -  May 29, 2024 - Abstract #EULAR2024EULAR_4433;    
    Long-standing gout appears to increase this risk. Additional prospective studies on a larger scale and broader assessments of BMD in individuals with gout are necessary to ascertain this association.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    TREATMENT SEQUENCE PATTERNS OF URATE-LOWERING THERAPY FOR GOUT BASED ON A COMMON DATA MODEL () -  May 29, 2024 - Abstract #EULAR2024EULAR_2988;    
    Our study shows the difference in first-line ULA between centers, yet febuxostat eventually was the predominantly used ULA in real-world practice. Furthermore, the sequence of urate-lowering therapy varied depending on the initial agent, baseline serum urate level, or renal function.
  • ||||||||||  ULTrA (URATE LOWERING THERAPY TO ACUTE TREATMENT RATIO)  () -  May 29, 2024 - Abstract #EULAR2024EULAR_2958;    
    Gout management is suboptimal leading to high rates of hospitalisation, time off work and healthcare costs. We propose monitoring and targeting a novel ULTrA index to improve overall gout management.
  • ||||||||||  allopurinol / Generic mfg.
    Preclinical, Journal:  Mass Spectrometric Analysis of Purine Intermediary Metabolism Indicates Cyanide Induces Purine Catabolism in Rabbits. (Pubmed Central) -  May 24, 2024   
    Finally, plasma uric acid levels correlated strongly with those of lactic acid, an established clinical biomarker of cyanide exposure, in addition to a tissue biomarker of cyanide exposure (skeletal muscle cytochrome c oxidase redox state). Cumulatively, these findings not only shed light on the in vivo role(s) of cyanide but also have implications in the field of medical countermeasure (MCM) development.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Retrospective data, Review, Journal:  Influence of xanthine oxidase inhibitors on all-cause mortality in adults: a systematic review and meta-analysis. (Pubmed Central) -  May 21, 2024   
    However, subgroup analyses showed its beneficial effect in patients with chronic kidney disease (14% risk reduction) and hyperuricemia (14% risk reduction), but not in patients with heart failure (28% risk increase). Urate-lowering therapy reduces all-cause mortality among patients with hyperuricemia and chronic kidney disease, but it seems to increase mortality in patients with heart failure and should be avoided in this subgroup.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  Predicting gout flares in people starting allopurinol using the start-low go-slow dose escalation strategy. (Pubmed Central) -  May 20, 2024   
    Anti-inflammatory prophylaxis when starting allopurinol using the "start-low go-slow" dose escalation strategy may be best targeted at those who have had a gout flare in the month prior to starting allopurinol and are commencing allopurinol 100mg daily. For those with ongoing gout flares during the first six months of starting allopurinol who have not yet achieved serum urate target, a longer period of prophylaxis may be required.
  • ||||||||||  allopurinol / Generic mfg.
    Preclinical, Journal:  Mechanisms of epigallocatechin gallate (EGCG) in ameliorating hyperuricemia: insights into gut microbiota and intestinal function in a mouse model. (Pubmed Central) -  May 17, 2024   
    In this study, hyperuricemic mice induced by potassium oxonate (PO) were treated with EGCG or the anti-hyperuricemia medication allopurinol (AP) to investigate the mechanisms underlying their anti-hyperuricemic effects...Transcriptomic analysis of the intestinal epithelium identifies 191 differentially expressed genes (DEGs) in EGCG-treated mice, including 8 purine-related genes. This study elucidates the anti-hyperuricemic mechanisms of EGCG, particularly its influence on the gut microbiota and gene expression in the intestinal epithelium.
  • ||||||||||  febuxostat / Generic mfg., allopurinol / Generic mfg.
    Review, Journal:  Management of hypertension addressing hyperuricaemia: introduction of nano-based approaches. (Pubmed Central) -  May 16, 2024   
    By addressing hyperuricaemia, practitioners may subsidize the optimization of blood pressure regulation, which illustrates the importance of addressing UA levels as a valuable strategy within the broader context of hypertension management. In this analysis, we outlined the operational principles of effective xanthine oxidase inhibitors for the treatment of hyperuricaemia and hypertension, along with an exploration of the contribution of nanotechnology to this field.
  • ||||||||||  allopurinol / Generic mfg.
    Journal:  The experiences and perspectives of people with gout on urate self-monitoring. (Pubmed Central) -  May 15, 2024   
    Urate data was shared with doctors at the patient's discretion and helped inform clinical decisions, such as allopurinol dose changes. Further research on implementing urate self-monitoring in routine care would enable an evaluation of its impact on medication adherence and clinical outcomes, as well as inform gout management guidelines.